🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effectiveness of Risk-based Sequential Screening for Esophageal and Gastric Cancer

RecruitingNAAges 50 Years - 69 YearsAllPeking University Cancer Hospital & Institute
NCT06306755 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To evaluate the feasibility, applicability, effectiveness, and health-economic value of the risk-based sequential screening modality for esophageal and gastric cancers, the investigators aim to initiate a community-based randomized controlled trial in Xun County, Henan Province, which is a high-risk region of upper gastrointestinal cancer (UGIC) in northern China. A total of 258 target villages from all the 11 communities (townships and streets) in Xun County will be randomly selected and assigned to the sequential screening group and the universal screening group at a ratio of 2:1 and the total sample size will be 21,000. In the sequential screening group, participants in the top 50% risk level (i.e., stratified as the high-risk subgroup) will be offered a standard upper gastrointestinal endoscopic screening. In contrast, all participants in the universal screening group will receive

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Permanent residency in the target villages in Xun County, Henan Province, China; * Aged 50 to 69 at the enrollment; * Voluntarily participate in this study and provide informed consent. Exclusion Criteria: * Had a history of endoscopic examination within 5 years prior to the initial interview; * Had a history of cancer; * Had a history of mental disorder; * Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV); * Had severe cardiovascular and cerebrovascular diseases; * Had severe respiratory disease, dyspnea, or asthmaticus status; * Had retropharyngeal abscess, severe spinal deformity, or aortic aneurysm; * With physical debility unable to tolerate endoscopic examination, or with difficulty in achieving sedation and self-control; * In the acute phase of corrosive inflammation of the upper gastrointestinal tract, or with suspected perforation of the upper gastrointestinal tract; * Had massive ascites, severe abdominal distension, or severe esophageal varices; * Pregnancy; * Had severe history of allergies; * Had propensity for bleeding (coagulopathy); * Others unable to tolerate the clinical examinations involved in this study.
💊

What it tests

  • Risk Assessment and Individualized Surveillance
  • Universal screening
📍

Where

1 site
Department of genetics, Peking University Cancer Hospital & Institute
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy